Helicobacter pylori antibody titer and gastric cancer screening

Hiroshi Kishikawa, Kayoko Hukuhara, Sakiko Takarabe, Shogo Kaida, Jiro Nishida

研究成果: Review article

14 引用 (Scopus)

抄録

The "ABC method" is a serum gastric cancer screening method, and the subjects were divided based on H. pylori serology and atrophic gastritis as detected by serum pepsinogen (PG): Group A [H. pylori (-) PG (-)], Group B [H. pylori (+) PG (-)], Group C [H. pylori (+) PG (+)], and Group D [H. pylori (-) PG (+)]. The risk of gastric cancer is highest in Group D, followed by Groups C, B, and A. Groups B, C, and D are advised to undergo endoscopy, and the recommended surveillance is every three years, every two years, and annually, respectively. In this report, the reported results with respect to further risk stratification by anti-H. pylori antibody titer in each subgroup are reviewed: (1) high-negative antibody titer subjects in Group A, representing posteradicated individuals with high risk for intestinal-type cancer; (2) high-positive antibody titer subjects in Group B, representing active inflammation with high risk for diffuse-type cancer; and (3) low-positive antibody titer subjects in Group C, representing advanced atrophy with increased risk for intestinal-type cancer. In these subjects, careful follow-up with intervals of surveillance of every three years in (1), every two years in (2), and annually in (3) should be considered.

元の言語English
記事番号156719
ジャーナルDisease Markers
2015
DOI
出版物ステータスPublished - 2015
外部発表Yes

Fingerprint

Pepsinogen A
Early Detection of Cancer
Helicobacter pylori
Stomach Neoplasms
Screening
Antibodies
Intestinal Neoplasms
Pepsinogens
Pepsinogen C
Endoscopy
Atrophic Gastritis
Serology
Serum
Atrophy
Inflammation
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

これを引用

Helicobacter pylori antibody titer and gastric cancer screening. / Kishikawa, Hiroshi; Hukuhara, Kayoko; Takarabe, Sakiko; Kaida, Shogo; Nishida, Jiro.

:: Disease Markers, 巻 2015, 156719, 2015.

研究成果: Review article

Kishikawa, Hiroshi ; Hukuhara, Kayoko ; Takarabe, Sakiko ; Kaida, Shogo ; Nishida, Jiro. / Helicobacter pylori antibody titer and gastric cancer screening. :: Disease Markers. 2015 ; 巻 2015.
@article{9ecf4586d3dc4fa985809525b0caf8fb,
title = "Helicobacter pylori antibody titer and gastric cancer screening",
abstract = "The {"}ABC method{"} is a serum gastric cancer screening method, and the subjects were divided based on H. pylori serology and atrophic gastritis as detected by serum pepsinogen (PG): Group A [H. pylori (-) PG (-)], Group B [H. pylori (+) PG (-)], Group C [H. pylori (+) PG (+)], and Group D [H. pylori (-) PG (+)]. The risk of gastric cancer is highest in Group D, followed by Groups C, B, and A. Groups B, C, and D are advised to undergo endoscopy, and the recommended surveillance is every three years, every two years, and annually, respectively. In this report, the reported results with respect to further risk stratification by anti-H. pylori antibody titer in each subgroup are reviewed: (1) high-negative antibody titer subjects in Group A, representing posteradicated individuals with high risk for intestinal-type cancer; (2) high-positive antibody titer subjects in Group B, representing active inflammation with high risk for diffuse-type cancer; and (3) low-positive antibody titer subjects in Group C, representing advanced atrophy with increased risk for intestinal-type cancer. In these subjects, careful follow-up with intervals of surveillance of every three years in (1), every two years in (2), and annually in (3) should be considered.",
author = "Hiroshi Kishikawa and Kayoko Hukuhara and Sakiko Takarabe and Shogo Kaida and Jiro Nishida",
year = "2015",
doi = "10.1155/2015/156719",
language = "English",
volume = "2015",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

TY - JOUR

T1 - Helicobacter pylori antibody titer and gastric cancer screening

AU - Kishikawa, Hiroshi

AU - Hukuhara, Kayoko

AU - Takarabe, Sakiko

AU - Kaida, Shogo

AU - Nishida, Jiro

PY - 2015

Y1 - 2015

N2 - The "ABC method" is a serum gastric cancer screening method, and the subjects were divided based on H. pylori serology and atrophic gastritis as detected by serum pepsinogen (PG): Group A [H. pylori (-) PG (-)], Group B [H. pylori (+) PG (-)], Group C [H. pylori (+) PG (+)], and Group D [H. pylori (-) PG (+)]. The risk of gastric cancer is highest in Group D, followed by Groups C, B, and A. Groups B, C, and D are advised to undergo endoscopy, and the recommended surveillance is every three years, every two years, and annually, respectively. In this report, the reported results with respect to further risk stratification by anti-H. pylori antibody titer in each subgroup are reviewed: (1) high-negative antibody titer subjects in Group A, representing posteradicated individuals with high risk for intestinal-type cancer; (2) high-positive antibody titer subjects in Group B, representing active inflammation with high risk for diffuse-type cancer; and (3) low-positive antibody titer subjects in Group C, representing advanced atrophy with increased risk for intestinal-type cancer. In these subjects, careful follow-up with intervals of surveillance of every three years in (1), every two years in (2), and annually in (3) should be considered.

AB - The "ABC method" is a serum gastric cancer screening method, and the subjects were divided based on H. pylori serology and atrophic gastritis as detected by serum pepsinogen (PG): Group A [H. pylori (-) PG (-)], Group B [H. pylori (+) PG (-)], Group C [H. pylori (+) PG (+)], and Group D [H. pylori (-) PG (+)]. The risk of gastric cancer is highest in Group D, followed by Groups C, B, and A. Groups B, C, and D are advised to undergo endoscopy, and the recommended surveillance is every three years, every two years, and annually, respectively. In this report, the reported results with respect to further risk stratification by anti-H. pylori antibody titer in each subgroup are reviewed: (1) high-negative antibody titer subjects in Group A, representing posteradicated individuals with high risk for intestinal-type cancer; (2) high-positive antibody titer subjects in Group B, representing active inflammation with high risk for diffuse-type cancer; and (3) low-positive antibody titer subjects in Group C, representing advanced atrophy with increased risk for intestinal-type cancer. In these subjects, careful follow-up with intervals of surveillance of every three years in (1), every two years in (2), and annually in (3) should be considered.

UR - http://www.scopus.com/inward/record.url?scp=84945218881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945218881&partnerID=8YFLogxK

U2 - 10.1155/2015/156719

DO - 10.1155/2015/156719

M3 - Review article

C2 - 26494936

AN - SCOPUS:84945218881

VL - 2015

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

M1 - 156719

ER -